Table 3. Meta-analysis results of the correlation of decreased GAS5 expression with clinicopathological parameters.
| Clinicopathological parameter | Sample size | OR (95% CI) | P | Heterogeneity | |
|---|---|---|---|---|---|
| I2 | Ph | ||||
| Age (≥ 60 vs. < 60) |
344 | 0.90 (0.58–1.40) | 0.645 | 9.9% | 0.350 |
| Gender (Male vs. Female) |
659 | 1.43 (0.98–2.00) | 0.059 | 0.0% | 0.917 |
| Clinical stage (I/II vs. III/IV) |
604 | 0.26 (0.18–0.38) | < 0.001 | 0.0% | 0.608 |
| Differentiation (Poor vs. Well/Moderate) |
602 | 1.98 (1.40–2.80) | < 0.001 | 48.4% | 0.050 |
| Lymph node metastasis (Yes vs. No) |
802 | 1.92 (1.44–2.57) | < 0.001 | 77.6% | < 0.001 |
| Distant metastasis (Yes vs. No) |
290 | 2.7 (1.05–6.97) | 0.040 | 2.4% | 0.38 |
| Tumor size (≥ 5 cm vs. < 5 cm) |
395 | 3.21 (2.08–4.95) | < 0.001 | 13.9% | 0.325 |